

Special Issue

Novel Research on the Diagnosis and Treatment of Melanoma

Message from the Guest Editors

Melanoma is the deadliest form of skin cancer, and it is thus critical to diagnose and treat it at the earliest stage of its development. In recent decades, enormous progress has been achieved in the diagnosis and treatment of melanoma. Recent advancements in noninvasive diagnostic strategies have helped to increase sensitivity for the early detection of melanoma and reduce unnecessary surgical procedures, especially in patients with ambiguous melanocytic lesions. Surgery remains the standard therapy in patients with a localized disease but is not curative for advanced melanoma. In the last ten years, developments in checkpoint inhibition and targeted therapy against melanoma have revolutionized the management of patients with advanced disease. The aim of this Special Issue is to publish original research articles, reviews, hypotheses, communications and editorial letters to provide new insights into the diagnosis and treatment of melanoma.

Guest Editors

Dr. Roberta Giuffrida

Dr. Stefania Guida

Dr. Caterina Dianzani

Dr. Claudio Conforti

Deadline for manuscript submissions

5 November 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/185828

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)